| Recruiting | Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life NCT06710418 | University of Washington | N/A |
| Not Yet Recruiting | Pre-emptive Anakinra for Cytokine Event Reduction NCT06703216 | Ann & Robert H Lurie Children's Hospital of Chicago | Phase 1 / Phase 2 |
| Recruiting | In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies NCT07239323 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Recruiting | Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to t NCT06317662 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia NCT06940960 | Affiliated Hospital of Guangdong Medical University | N/A |
| Recruiting | A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Child NCT06124157 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia NCT06890065 | Shenzhen Genocury Biotech Co., Ltd. | N/A |
| Unknown | CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL). NCT06078306 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Recruiting | Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma NCT05602194 | Children's Oncology Group | Phase 3 |
| Active Not Recruiting | Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy fo NCT05303792 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Active Not Recruiting | CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission NCT05707273 | City of Hope Medical Center | Phase 1 |
| Recruiting | Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults NCT05310591 | Assistance Publique - Hôpitaux de Paris | Phase 1 / Phase 2 |
| Completed | Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-AL NCT05557110 | Chen Suning | Phase 2 |
| Recruiting | Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed NCT04872790 | OHSU Knight Cancer Institute | Phase 1 |
| Recruiting | Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukem NCT05281809 | John Lister | Phase 2 |
| Recruiting | Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Le NCT05157971 | City of Hope Medical Center | Phase 1 |
| Unknown | Monitoring Minimal Residual Disease（MRD）in Pediatric B-acute Lymphoblastic Leukemia NCT04977895 | Sun Yat-sen University | — |
| Completed | TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL) NCT04557436 | Great Ormond Street Hospital for Children NHS Foundation Trust | Phase 1 |
| Recruiting | Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenoty NCT03959085 | Children's Oncology Group | Phase 3 |
| Terminated | Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Tra NCT03856216 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lympho NCT03914625 | National Cancer Institute (NCI) | Phase 3 |
| Withdrawn | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase NCT02538926 | University of Washington | Phase 2 |
| Terminated | Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia NCT03488225 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residu NCT03441061 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refr NCT04184414 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | EARLY_Phase 1 |
| Active Not Recruiting | Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refrac NCT03241940 | Stanford University | Phase 1 |
| Suspended | Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphob NCT03150693 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Active Not Recruiting | CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refract NCT03233854 | Stanford University | Phase 1 |
| Active Not Recruiting | Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromoso NCT03007147 | Children's Oncology Group | Phase 3 |
| Completed | CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) NCT03289455 | Autolus Limited | Phase 1 / Phase 2 |
| Completed | Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia NCT02484430 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene NCT02828358 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia NCT02767934 | University of Washington | Phase 2 |
| Recruiting | Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients Wi NCT02877303 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia NCT02618109 | University Hospital, Angers | Phase 4 |
| Completed | Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease NCT02458014 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patient NCT02143414 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia NCT02968472 | The First People's Hospital of Yunnan | Phase 1 |
| Active Not Recruiting | Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia NCT02146924 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leuke NCT02883049 | National Cancer Institute (NCI) | Phase 3 |